logo
logo
TKNO stock ticker logo

Alpha Teknova, Inc.

NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
連絡先情報
2451 Bert Dr., Hollister, CA, 95023, United States
831-637-1100
www.teknova.com
時価総額
$148.44M
PER (TTM)
-8.6
14.3
配当利回り
--
52週高値
$7.48
52週安値
$1.91
52週レンジ
15%
順位48Top 64.4%
3.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 3.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$9.98M+0.00%
直近4四半期の推移

EPS

-$0.09+0.00%
直近4四半期の推移

フリーCF

-$710.00K+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Achieved Revenue reached $40.520M, increasing 7.4% from $37.745M in 2024, driven by Lab Essentials segment growth.
Gross Margin Expansion Gross profit increased 85.9% to $13.441M; margin improved significantly to 33.2% from 19.2% reported.
Net Loss Reduction Net loss reduced by $9.486M to $(17.259)M, reflecting a 35.5% improvement in overall operating results.
Positive Investing Cash Flow Net cash provided by investing activities was $10.700M, resulting from $29.000M in short-term investment maturities.

リスク要因

Historical Losses Persist Past operating losses incurred; future profitability uncertain if revenue growth fails to offset increasing operating expenses.
Supply Chain Disruption Risk Supply chain disruption from natural disasters or catastrophic events could negatively affect production, delivery, and product demand.
Customer Relationship Reliance Reliance on customer relationships; termination of major orders could cause temporary or permanent revenue loss.
Uncertain Future Capital Needs Future capital needs are uncertain; financing may be required but securing favorable terms is not assured.

見通し

Deepen Customer Workflow Integration Strategy focuses on increasing integration of custom and GMP products into customer development workflows for sustained growth.
Selective Geographic Expansion Plan to expand geographic reach outside the U.S., targeting select European markets with local supply gaps.
Growth in Therapeutic Modalities Expect growth driven by continued R&D investment in cell/gene therapy, mRNA, and molecular diagnostics markets.
Infrastructure Investment Commit to operational excellence via infrastructure investment to increase capacity and reduce custom product turnaround times.

同業比較

売上高 (TTM)

NEO stock ticker logoNEO
$727.33M
+10.1%
IRWD stock ticker logoIRWD
$296.15M
-15.7%
CGC stock ticker logoCGC
$278.39M
+0.6%

粗利益率 (最新四半期)

IRWD stock ticker logoIRWD
99.0%
+32.6pp
CVRX stock ticker logoCVRX
86.3%
+3.6pp
PRQR stock ticker logoPRQR
85.5%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CGC$524.81M-1.5-52.9%23.1%
IRWD$516.89M21.4-8.2%150.6%
SOPH$351.89M-4.2-117.0%38.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月14日
|
EPS:-$0.08
|
売上高:$10.19M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし